In the last decade, interventions involving orthobiologics, like platelet rich plasma (PRP), have been providing relief and new hope for tissue and joint damage. Many patients with conditions like osteoarthritis, degenerative disc disease and tendinosis are finding significant, long-term improvement from orthobiologics the use of natural substances like platelets and stem cells to help musculoskeletal injuries heal.
Dr. Matthew Gnirke, a physiatrist at Vail-Summit Orthopaedics & Neurosurgery, specializes in orthobiologics. He employs PRP and bone marrow aspirate concentrate (BMAC) to get people back to the sports and activities they love.
What is it?
PRP and BMAC both use platelets from the patients own body.
PRP interventions involve a simple blood draw about 60cc, which is anticoagulated (to prevent blood clotting) and spun to separate different cell types. Physicians then collect the platelets, which are the least dense cells, and inject them into a joint or other damaged site.
BMAC interventions also use platelets, along with a small amount of stem cells; these mesenchymal stem cells have the ability to differentiate (or turn into) cells that produce cartilage, tendons, ligaments and muscles. They are sourced from bone marrow through a needle. The procedure can be done in office, or, if a patient prefers sedation, in a surgical setting.
BMAC is not a surgical procedure, but it can cause pain, he said. The response is highly variable. Many patients describe it as a deep Charlie horse in the buttock. Some feel it less, some more, but the vast majority of patients do tolerate it in the office and sedation is not necessary.
BMAC is often used for more advanced osteoarthritis and disc diseases, whereas PRP is used for early stage osteoarthritis, joint issues and tendon disorders like tendinosis (the latter of which is caused by degeneration of a tendons collagen from chronic overuse, such as tennis elbow).
Platelets act like microscopic, natural surgeons, Gnirke said. They attach to damaged collagen fibers, which are the fundamental building blocks of tendons, ligaments and muscles. One platelet contains over 1,200 growth factors within it, he said. PRP treatment typically releases at least 1 million platelets into an injured area, releasing growth factors involved in collagen repair and synthesis.
They are truly wound-healing cells, Gnirke said.
What can it help?
Orthobiologics are referred to as regenerative medicine because they actually help heal rather than simply masking symptoms like steroid shots do. They are used to treat damaged tendons, ligaments, muscles, joints and discs.
Gnirke has seen patients with early stage osteoarthritis of the knee and other joints, as well as conditions like tennis elbow, improve significantly. These conditions result from slow degradation over time, as collagen fibers lose strength and density and tend to get microtears.
The earlier you catch it, the more likely youre able to see long term trajectory changing improvement, he said.
He recommends people come in for an evaluation as soon as symptoms affect them regularly or impact function. Even if you can still ski, bike, hike and do what you love, if youre modifying movements or aware of discomfort, it often indicates mild to moderate disease, he said. Grinning and bearing pain or stiffness could lead to further breakdown of tissues and joints, which can progress to more severe osteoarthritis (like bone on bone knee damage) or severe disc degeneration and associated pain.
Gnirke finds orthobiologics quite effective for lower back pain related to degenerative disc disease, he said. Studies show an improvement in back pain in two out of three patients over the long term.
In the past, physical therapy and/or anti-inflammatories, then surgery was used to treat degenerative disc disease there werent many options in-between. Orthobiologics bridge that gap.
Originally used in sports medicine for professional athletes, PRP and BMAC are now available to the general public. Though most insurances still view them as experimental treatments, workmans compensation insurance and Kaiser Permanente are paving the way for other companies to cover the procedures. No one knows when (or if) that will happen, but its still probably years away. Until then, patients can pay out of pocket (usually under $1,000 for PRP).
Studies show that 65% to 75% of patients respond positively to PRP and BMAC.
Over 2/3 of patients see significant, long-term improvement for greater than one to two years, Gnirke said.
How the procedure works
Once platelets (and stem cells, in the case of BMAC) are collected, Gnirke delivers injections into the site of injury, using ultrasound or x-ray to ensure the exact site of injection.
Patients often temporarily feel worse before they get better: Pain flare ups range from mild to severe and can last anywhere from one day to up to two weeks. The longer, more severe reactions usually occur with spinal injections, he said. Within a month, patients usually feel theyre at baseline: not better, not worse.
Typically, it takes about six to eight weeks to start feeling improvement; it can take four to six months, and even up for a year if its a spinal injection, for improvements to fully take effect. Of course, regenerative medicine is just one of the procedures Gnirke employs. His practice focuses on proper diagnosis, prevention, treatment and rehabilitation of musculoskeletal injuries and disorders. He avoids overtreating and doesnt believe in preemptive orthobiologics where theyre not needed. His main interest: getting people back to doing what they love.
- Cellino is using AI and machine learning to scale production of stem cell therapies - TechCrunch - September 22nd, 2021
- Capping Medicare Part B payments will limit outpatient access to CAR-T - STAT - September 22nd, 2021
- Treating Patients with High-Risk Myelodysplastic Syndrome - Targeted Oncology - September 22nd, 2021
- FDA Issues Draft Guidance on Donor Eligibility and Manufacturing of Cellular Therapies for Animals | FDA - FDA.gov - September 22nd, 2021
- CD19 As a Targeted Agent in CAR T Cell Therapy for R/R DLBCL - Targeted Oncology - September 22nd, 2021
- Stem Rx Bioscience Solutions successfully use cell-based therapy for age-related macular degeneration and restoration of vision - Financial Express - September 22nd, 2021
- Repeated injury to the epithelial tissue of airways causes "biological aging" of stem cells - News-Medical.net - September 22nd, 2021
- Revival of the cell and gene therapy field opens new avenues for repairing the Parkinsonian brain - News-Medical.Net - September 22nd, 2021
- Scientists Awarded The Albany Prize, America's Most Distinguished Prize in Medicine, for Research Leading to Covid-19 Vaccines - Albany Medical Center - September 22nd, 2021
- Why I Believe It Is Wrong To Take The COVID Vaccine - And Response - The Chattanoogan - September 22nd, 2021
- How can fertility counseling be implemented for every newly diagnosed pediatric patient facing gonadotoxic ... - Physician's Weekly - September 20th, 2021
- Mantle Cell Lymphoma Treatment in the Era of COVID-19 - Curetoday.com - September 20th, 2021
- Calloway County Health Department announces 23 new cases of COVID-19 - Murray Ledger and Times - September 20th, 2021
- Effects of Leukemia on Your Body - Healthline - September 20th, 2021
- DCGI approves stem cell-based therapy trial for COVID-19 pneumonia treatment - BSI bureau - September 17th, 2021
- Dr. Anderson on the Challenges Faced With CAR T-Cell Therapy in Myeloma - OncLive - September 17th, 2021
- Treatment Methods: Transplant Eligibility in R/R DLBCL and CAR T Cell Therapy - Targeted Oncology - September 17th, 2021
- Insights into the cellular and molecular changes in male infertility - EurekAlert - September 17th, 2021
- Loss of Vision Caused by AMD: Cell-Based Therapy Can Help Restore Your Eyesight - TheHealthSite - September 17th, 2021
- The Promise of Regenerative Medicine to Treat Chronic Pain - Newswise - September 17th, 2021
- Researchers build the ovarian environment using mouse stem cells - News-Medical.net - September 17th, 2021
- Molecular and Cellular Changes in the Testicular Tissue of Infertile Men Revealed - Technology Networks - September 17th, 2021
- Magenta Therapeutics Announces IND Clearance for MGTA-117 Targeted Conditioning Clinical Trial - Yahoo Finance - September 17th, 2021
- Indolent lymphoma: Symptoms, outlook, treatment, and more - Medical News Today - September 17th, 2021
- Dr. Shah on Unmet Needs With CAR T-Cell Therapy in Multiple Myeloma - OncLive - September 17th, 2021
- Researchers focus on improving biomaterials used for bone and tissue repair - News-Medical.net - September 17th, 2021
- Dr. Kahl on Patient Selection for Intensive Vs Non-Intensive Treatment in MCL - OncLive - September 17th, 2021
- Orchard Therapeutics Outlines Differentiated Profile of Its HSC Gene Therapy Approach and ... - The Bakersfield Californian - September 14th, 2021
- Meet the Finnish team using stem cells to cure blindness - Sifted - September 14th, 2021
- Why you should feel optimistic about the future of healthcare - Say - Say Communications - September 14th, 2021
- Treating Hearing Loss: The Hunt for Drugs That Promote Hair Cell Regeneration - Technology Networks - September 14th, 2021
- Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and... - September 14th, 2021
- Celebrating the End of Cancer Treatment - Curetoday.com - September 14th, 2021
- BlueCross Will Cover Costs for COVID-19 Booster - Business Wire - September 14th, 2021
- UAB opening vaccination sites in Hoover and Ensley - UAB News - September 12th, 2021
- CardiAMP Cell Therapy Heart Failure Trial to be Featured in Two Presentations at Heart Failure Society of America Annual Meeting 2021 - Yahoo Finance - September 10th, 2021
- A Knee or Hip Replacement Without Surgery? Its on the Horizon - The Wall Street Journal - September 10th, 2021
- Jerry Nelson: Stem cell treatment can be alternative to joint replacement - Watertown Public Opinion - September 10th, 2021
- Graft Vs Host Prophylaxis With Posttransplant Cyclophosphamide Not Associated With Increased Infection Risk - Hematology Advisor - September 10th, 2021
- Carolina Researchers Lead CZI Collaborative on Childhood Diseases | Newsroom - UNC Health and UNC School of Medicine - September 10th, 2021
- A New Opportunity To Receive Sight - mvprogress - September 8th, 2021
- Japan: A case study of national readiness for regenerative medicine - Open Access Government - September 8th, 2021
- Merger Proposals Blocked By Cell Therapies Developer - Labmate Online - September 8th, 2021
- Using Predictive, Data Analytics to Expand Knowledge of Alzheimer's - HealthITAnalytics.com - September 8th, 2021
- Research on preterm brain injury treatment recognised - Medicine, Nursing and Health Sciences - Monash University - September 8th, 2021
- Roche bets $300M on Adaptimmune tech for off-the-shelf cell therapies for cancer - MedCity News - September 8th, 2021
- Desperate family have just three weeks to find stem cell donor for their girl - Express - September 8th, 2021
- Ivy Tech nursing student among 234 who want religious exemption to vaccine mandate - The Indianapolis Star - September 8th, 2021
- Convection Improves Survival and Insulin Secretion of Beta Cell Implants - Genetic Engineering & Biotechnology News - September 8th, 2021
- Bone Therapeutics reports half year 2021 results - GlobeNewswire - September 8th, 2021
- How a Family's Persistence Led to Their Son's Successful Sickle Cell TreatmentWith the Help of My Special Aflac Duck EBONY - EBONY - September 8th, 2021
- Leukemia Awareness Month: Changing the Future of AML through Precision Medicine - Targeted Oncology - September 8th, 2021
- Third Line Therapies in R/R FL - Cancer Network - September 8th, 2021
- BMS opts-in on Evotec's neurodegenerative medicine - PharmaTimes - September 7th, 2021
- New Cancer Treatments May Be on The Horizon Thanks to Success in mRNA Vaccine Trial - Good News Network - September 7th, 2021
- Billionaires Have Reportedly Invested In A BioTech Company Aiming To Reverse Aging - IFLScience - September 7th, 2021
- Human Mini-Lungs Grown in Lab Dishes are Closest Yet to Real Thing - UC San Diego Health - September 1st, 2021
- Targeting and inhibiting a protein could provide more effective treatment for brain cancer - News-Medical.Net - September 1st, 2021
- Could gene therapies be used to cure more people with HIV? - aidsmap - September 1st, 2021
- BioRestorative Therapies Receives Patent in Japan Related to its Off-the-Shelf ThermoStem Program - Yahoo Finance - September 1st, 2021
- Future Therapeutic Options for Diffuse Large B-Cell Lymphoma - Targeted Oncology - September 1st, 2021
- COVID-19 Causes Severe Disease, Disrupted Treatment in Children with Cancer - Pharmacy Times - September 1st, 2021
- Blood cancer and its impact on female fertility - Lexology - September 1st, 2021
- New gene therapies may soon treat dozens of rare diseases, but million-dollar price tags will put them out of reach for many - The Conversation US - September 1st, 2021
- Global Cryopreservation Equipment Market Report 2021-2028 - Growing Acceptance for Regenerative Medicine & Increasing Needs of Biobanking... - August 30th, 2021
- Bengaluru boy with rare disease meets his German stem cell donor - The Hans India - August 30th, 2021
- Novartis falls behind rivals in race to bring CAR-T to early lymphoma - BioPharma Dive - August 30th, 2021
- Mike Tysons weird stem cell treatment has helped transform incredible body at 55 - Daily Star - August 28th, 2021
- University of Miami Researchers Enter Phase 3 of Stem Cell Clinical Trial in Treating COVID-19 Acute Respiratory Distress Syndrome - Newswise - August 28th, 2021
- Incyte and MorphoSys Announce the European Commission Approval of Minjuvi (tafasitamab) in Combination With Lenalidomide for the Treatment of Adults... - August 28th, 2021
- College of Medicine University of Central Florida Research Wounds Heal Faster with New Treatment: Military Medicine Discovery - PRNewswire - August 28th, 2021
- Lab-grown minibrains with eyes may advance personalized drug testing, researchers say - Mahoning Matters - August 28th, 2021
- Off-the-Shelf NK Cell Products FT596 and FT516 Show Early Promise in B-cell Lymphoma - OncLive - August 28th, 2021
- BioMarin stands tall with first approved drug for rare disease that causes dwarfism - MedCity News - August 28th, 2021
- What to know about the third COVID-19 shot in Gainesville, Alachua County - Gainesville Sun - August 28th, 2021
- Department of Public Health Offering Third Dose COVID-19 Vaccines to Eligible Individuals | Monroe County, NY - monroecounty.gov - August 28th, 2021
- Cell Culture Protein Surface Coating Market | Know the Diverse Growth Parameters Influencing the Market - BioSpace - August 23rd, 2021
- County providing COVID-19 third dose booster to immunocompromised - City of Fort Worth - August 23rd, 2021
- Outcomes For MCL Patients and Impact of Relapse Timing After Transplant on OS - Targeted Oncology - August 23rd, 2021
- SGMC Offering COVID-19 Third Dose to Immunocompromised People - sgmc.org - August 23rd, 2021